GlassScriptPhysician profile
Kevin L Konzen
NPI 1033102702
$6,563.05
in general payments reported to CMS, 2019-2025
30 companies · $596 in 2025
The $596 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $702 · 2021: $1,300 · 2022: $854 · 2023: $962 · 2024: $1,598 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,734.01 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $510.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $400.54 | 2021-2024 | |
| Abbott Laboratories | $224.43 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $223.76 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $220.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $200.63 | 2020 | |
| Dexcom, INC. | $128.87 | 2023-2025 | Dexcom G6 Transmitter |
| Recor Medical INC | $99.96 | 2024 | Paradise Renal Denervation System |
| Astellas Pharma US INC | $97.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $91.57 | 2024 | |
| Sanofi-Aventis U.S. LLC | $82.93 | 2021-2024 | |
| Medtronic, INC. | $69.98 | 2022-2023 | Intellis Adaptivestim |
| Radius Health, INC. | $68.78 | 2024-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.21 | 2020-2025 | Jardiance, Synjardy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.64 | 2024-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $43.12 | 2020-2021 | |
| Beta Bionics, INC. | $35.61 | 2024 | Ilet Bionic Pancreas |
| Glaxosmithkline, LLC. | $33.78 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $31.45 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $20.82 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $17.33 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.96 | 2021 | |
| Lifescan, INC. | $16.89 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.86 | 2021 | |
| Amarin Pharma, INC. | $14.32 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2024 | Horizant |
| Amneal Pharmaceuticals LLC | $13.12 | 2021 | |
| Merck Sharp & Dohme LLC | $12.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Konzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.